Pfenex Inc (NYSEMKT:PFNX) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Pfenex (NYSEMKT:PFNX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.06). The business had revenue of $3.03 million for the quarter, compared to analyst estimates of $3.10 million. Pfenex had a negative return on equity of 75.61% and a negative net margin of 406.87%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.43) EPS. On average, analysts expect Pfenex to post $-2.09 EPS for the current fiscal year and $-2.48 EPS for the next fiscal year.

Shares of Pfenex Inc (PFNX) opened at 2.91 on Tuesday. The firm has a market cap of $68.47 million, a PE ratio of 46.94 and a beta of 4.65. The stock’s 50 day moving average is $3.01 and its 200 day moving average is $3.97. Pfenex Inc has a 12 month low of $2.54 and a 12 month high of $11.35.

Several research firms recently commented on PFNX. Zacks Investment Research raised Pfenex from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, October 24th. William Blair reissued an “ourperform” rating on shares of Pfenex in a research report on Friday, September 8th. Finally, ValuEngine lowered Pfenex from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

COPYRIGHT VIOLATION WARNING: This article was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at

Pfenex Company Profile

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Earnings History for Pfenex (NYSEMKT:PFNX)

Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.